Cite
APA Citation
Puzanov, I., Chesney, J., Collichio, F., Singh, P., Milhem, M., Glaspy, J., Hamid, O., Ross, M., Friedlander, P., Garbe, C., Logan, T., Hauschild, A., Lebbe, C., Yi, M., Snyder, W., & Mehnert, J. (n.d.). 433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial. Journal for immunotherapy of cancer, 8, A263–A264. http://access.bl.uk/ark:/81055/vdc_100144722043.0x000004